aspirin + pterostilbene

Aspirin + pterostilbene is an experimental oral combination of the nonsteroidal anti-inflammatory drug aspirin with the polyphenolic stilbenoid pterostilbene, intended to exploit complementary antiplatelet, anti-inflammatory, and chemopreventive properties. Aspirin irreversibly acetylates and inhibits cyclooxygenase-1 and cyclooxygenase-2, suppressing thromboxane A2 and prostaglandin synthesis, while pterostilbene, a dimethoxy analog of resveratrol, exhibits antioxidant, anti-inflammatory, metabolic, and anticancer activities via modulation of oxidative stress pathways, apoptotic and autophagic signaling, and nuclear receptors. Preclinical work has examined both covalent aspirin–stilbene conjugates and simple co-administration of aspirin with pterostilbene for enhanced inhibition of cancer cell growth, but there is no established approved medicinal product under this exact combination name.